Endocrinology

Top Story

Ascensia, Voluntis to combine technologies

June 24, 2017

Ascensia Diabetes Care and Voluntis are initiating a technology partnership, linking their blood glucose monitors and insulin management system, according to a press release from the two companies.

Under the agreement, Ascencia’s Contour line of glucose monitors will connect via Bluetooth to Voluntis’s Insulia, a basal insulin manager, which will allow people with type 2 diabetes to manage their basal insulin dosing with accurate glucose data, according to the release.

In the Journals Plus

Several medications safe for comanagement of type 2 diabetes, osteoporosis

June 23, 2017
A recent comprehensive review published in The Journal of Clinical Endocrinology & Metabolism identifies metformin, sulfonylureas, DPP-IV inhibitors and GLP-1…
In the Journals Plus

Maintained weight loss for 1 year increases insulin sensitivity in women

June 23, 2017
Women with overweight or obesity who maintained at least 15% reduction in body weight for 12 months were more likely to have improved insulin sensitivity when compared…
In the Journals Plus

Childhood fractures not predictive of BMD, bone strength in young men

June 23, 2017
The occurrence of fractures in boys did not predict bone fragility of men in early adulthood, study data from Switzerland and the Netherlands showed.
Meeting News

Strategies to encourage more patients to undergo eye tests

June 23, 2017
PHILADELPHIA — Education, along with a screening reminder card, may encourage more patients to get diabetic retinopathy eye screening exams, according to a…
More News Headlines »
CME

Practical Lipidology®: Volume 3, Number 2

This activity is supported by an educational grant from Amgen

The reduction of low-density lipoprotein-cholesterol (LDL-C) is recognized as the primary strategy for decreasing…
More »
Video
Meeting News

VIDEO: Screening BMD crucial to diagnose fracture risk

May 3, 2017
More »
Featured
The Endocrine Society Annual Meeting

The Endocrine Society Annual Meeting

CME

Rapid Response from Austin: Expanding Options in Type 2 Diabetes Management

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Approximately 150 million people worldwide have diabetes mellitus and this number is expected to double by 2025…
More »
Current Issues
View the Current Issue
Advertisement
Advertisement